Intech Investment Management LLC grew its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 72.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 61,531 shares of the specialty pharmaceutical company’s stock after acquiring an additional 25,828 shares during the quarter. Intech Investment Management LLC owned 0.11% of Supernus Pharmaceuticals worth $3,058,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in Supernus Pharmaceuticals by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock worth $73,215,000 after acquiring an additional 62,875 shares in the last quarter. Jackson Creek Investment Advisors LLC acquired a new position in Supernus Pharmaceuticals during the fourth quarter worth about $451,000. Royce & Associates LP raised its stake in Supernus Pharmaceuticals by 385.1% during the fourth quarter. Royce & Associates LP now owns 197,737 shares of the specialty pharmaceutical company’s stock worth $9,828,000 after acquiring an additional 156,972 shares in the last quarter. Westover Capital Advisors LLC acquired a new position in Supernus Pharmaceuticals during the fourth quarter worth about $1,587,000. Finally, Hantz Financial Services Inc. raised its stake in Supernus Pharmaceuticals by 73.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 458 shares in the last quarter.
Insiders Place Their Bets
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 50,000 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $50.28, for a total transaction of $2,514,000.00. Following the transaction, the vice president directly owned 17,044 shares in the company, valued at approximately $856,972.32. This represents a 74.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Georges Gemayel sold 10,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $53.71, for a total value of $537,100.00. Following the transaction, the director owned 28,159 shares in the company, valued at $1,512,419.89. The trade was a 26.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 116,406 shares of company stock valued at $5,911,086 over the last 90 days. 8.80% of the stock is currently owned by corporate insiders.
Supernus Pharmaceuticals Stock Performance
Analysts Set New Price Targets
Several research analysts have commented on SUPN shares. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 23rd. Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Supernus Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $62.17.
Check Out Our Latest Report on SUPN
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
Featured Stories
- Five stocks we like better than Supernus Pharmaceuticals
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}